ESC 365 - Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in cancer patients with diabetes mellitus

Open Access

Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in cancer patients with diabetes mellitus

Session: Emerging insights in cardio-oncology: biomarkers, cardiotoxicity, and protective therapies

Topic: Cardio-Oncology

Speaker: Doctor M. Gvili Perelman (Tel Aviv, IL)

Event: Heart Failure 2025

Congress Presentation

Add to my library

About the speaker

Doctor Moran Gvili Perelman

Tel Aviv Sourasky Medical Center, Tel Aviv (Israel)

0 follower

6 more presentations in this session

Sacubitril-valsartan reduced H-FABP, hs-cTnT, hs-CRP and monocyte-to-lymphocyte ratio in anthracycline-treated preclinical models through NLRP3-mTOR-AKT pathways

Speaker: Doctor N. Maurea (Naples, IT)

Heart failure hospitalization and outcomes in cancer patients undergoing immune checkpoint inhibitor treatment: a systematic review and meta-analysis

Speaker: Doctor N. Sari (Jakarta, ID)

The predictive value of baseline troponin measurements in patients treated with immune checkpoint inhibitors

Speaker: Doctor M. Laufer-Perl (Tel Aviv, IL)

GLP1-RA associated with SGLT2i as new therapy of anthracycline-induced cardiotoxicity under hyperglycemia: biochemical and preclinical evidences

Speaker: Doctor N. Maurea (Naples, IT)

Evaluation of vascular cell adhesion molecule-1 (VCAM-1) level changes in patients with lymphoproliferative diseases during antitumor therapy

Speaker: Doctor R. Alieva (Tashkent, UZ)

Access the full session

Emerging insights in cardio-oncology: biomarkers, cardiotoxicity, and protective therapies

Speakers: Doctor M. Gvili Perelman, Doctor N. Maurea, Doctor N. Sari, Doctor M. Laufer-Perl, Doctor N. Maurea...

About the event

Heart Failure 2025

17 May - 20 May 2025

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources

Explore sponsored resources